CA3171894C - CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE - Google Patents

CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE

Info

Publication number
CA3171894C
CA3171894C CA3171894A CA3171894A CA3171894C CA 3171894 C CA3171894 C CA 3171894C CA 3171894 A CA3171894 A CA 3171894A CA 3171894 A CA3171894 A CA 3171894A CA 3171894 C CA3171894 C CA 3171894C
Authority
CA
Canada
Prior art keywords
cocrystal
cyano
phenyl
thiazol
ylcarbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3171894A
Other languages
English (en)
French (fr)
Other versions
CA3171894A1 (en
Inventor
Julio Castro Palomino Laria
Juan Camacho Gomez
Original Assignee
Palobiofarma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma SL filed Critical Palobiofarma SL
Publication of CA3171894A1 publication Critical patent/CA3171894A1/en
Application granted granted Critical
Publication of CA3171894C publication Critical patent/CA3171894C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/02Salts; Complexes; Addition compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3171894A 2020-03-16 2021-03-15 CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE Active CA3171894C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382194.7A EP3882240A1 (en) 2020-03-16 2020-03-16 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
EP20382194.7 2020-03-16
PCT/EP2021/056506 WO2021185748A1 (en) 2020-03-16 2021-03-15 Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid

Publications (2)

Publication Number Publication Date
CA3171894A1 CA3171894A1 (en) 2021-09-23
CA3171894C true CA3171894C (en) 2025-03-11

Family

ID=69953938

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171894A Active CA3171894C (en) 2020-03-16 2021-03-15 CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE

Country Status (21)

Country Link
US (1) US12384754B2 (https=)
EP (2) EP3882240A1 (https=)
JP (1) JP7779846B2 (https=)
KR (1) KR20220154791A (https=)
CN (1) CN115298169B (https=)
AU (1) AU2021237686B2 (https=)
BR (1) BR112022018449A2 (https=)
CA (1) CA3171894C (https=)
DK (1) DK4121419T3 (https=)
ES (1) ES3002084T3 (https=)
FI (1) FI4121419T3 (https=)
HR (1) HRP20241515T1 (https=)
HU (1) HUE068886T2 (https=)
LT (1) LT4121419T (https=)
MX (1) MX2022011530A (https=)
PL (1) PL4121419T3 (https=)
PT (1) PT4121419T (https=)
RS (1) RS66214B1 (https=)
SI (1) SI4121419T1 (https=)
WO (1) WO2021185748A1 (https=)
ZA (1) ZA202211247B (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331220B1 (es) 2007-10-02 2010-09-23 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska

Also Published As

Publication number Publication date
ES3002084T3 (en) 2025-03-06
JP7779846B2 (ja) 2025-12-03
KR20220154791A (ko) 2022-11-22
MX2022011530A (es) 2022-10-13
HUE068886T2 (hu) 2025-02-28
EP4121419A1 (en) 2023-01-25
CN115298169A (zh) 2022-11-04
FI4121419T3 (fi) 2024-11-04
US12384754B2 (en) 2025-08-12
LT4121419T (lt) 2024-11-25
EP3882240A1 (en) 2021-09-22
WO2021185748A1 (en) 2021-09-23
CN115298169B (zh) 2024-11-19
US20230183195A1 (en) 2023-06-15
DK4121419T3 (da) 2024-10-28
ZA202211247B (en) 2023-12-20
AU2021237686A1 (en) 2022-10-06
BR112022018449A2 (pt) 2022-11-01
AU2021237686B2 (en) 2026-04-09
HRP20241515T1 (hr) 2025-01-03
PL4121419T3 (pl) 2025-02-17
CA3171894A1 (en) 2021-09-23
EP4121419B1 (en) 2024-08-14
PT4121419T (pt) 2024-11-18
SI4121419T1 (sl) 2025-02-28
RS66214B1 (sr) 2024-12-31
JP2023517722A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
EP2603503B1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
KR20170061615A (ko) 피마살탄의 신규 염
KR20200074169A (ko) 4-(4-(1-이소프로필-7-옥소-1,4,6,7-테트라히드로스피로[인다졸-5,4'-피페리딘]-1'-카르보닐)-6-메톡시피리딘-2-일)벤조산의 결정질 2-아미노-2-(히드록시메틸)프로판-1,3-디올 염
US20210130330A1 (en) Solid forms of cerdulatinib
US11584779B2 (en) Solid state forms of voclosporin
CA3171894C (en) CARBOXYLIC ACID COCRISTALS (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOLE-2-YLCARBAMOYL)CYCLOPENTANE
EP3592734B1 (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
EP3652193A1 (en) New crystalline polymorphs of bardoxolone methyl
RU2182575C2 (ru) Псевдополиморфные формы дигидрохлорида 2-[2-[4-(бис-(4-фторфенил)метил)-1-пиперазинил]этокси]уксусной кислоты
EA045045B1 (ru) Сокристаллы (1r,3s)-3-(5-циано-4-фенил-1,3-тиазол-2-илкарбамоил)циклоопентанкарбоновой кислоты
KR20140022851A (ko) 오타믹사반의 벤조산염
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
WO2020198429A1 (en) Solid state forms of acalabrutinib
WO2019086509A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
HK40020652B (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid
HK40020652A (en) Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20240703

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240703

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240703

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250214

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250307

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250515

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260305

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260305